HONG KONG, July 24, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that the first patient has been enrolled in the pivotal/registration Phase III clinical trial (AK112-310/HARMONi-GI2) of ivonescimab, a first-in-class PD-1/VEGF bispecific antibody developed by the company. The trial is investigating ivonescimab...
LONDON, Jan. 14, 2025 /PRNewswire/ -- A new Competitive Ranking by global technology intelligence firm ABI Research has found that ZTE is the leading 5G...
PLANO, Texas, Jan. 14, 2025 /PRNewswire/ -- Argon Medical, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and...
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- Premium vegan beauty brand d'Alba has achieved significant growth in its overseas sales, rising to approximately KRW...
SEOUL, South Korea, Jan. 14, 2025 /PRNewswire/ -- ImmunoForge announced that it has received approval for the Phase 2 clinical trial IND for 'Pemziviptadil...